跳至主要内容
临床试验/NCT00112567
NCT00112567已完成1 期

A Phase I/II Study of Total Body Irradiation, Thiotepa, and Fludarabine as Conditioning for Haploidentical CD34+ Purified Peripheral Blood Stem Cell Transplants

Fred Hutchinson Cancer Center4 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2003年4月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
20
试验地点
4
主要终点
Safety

研究概览

简要总结

RATIONALE: Chemotherapy, such as fludarabine and thiotepa, and radiation therapy may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow. Giving healthy stem cells from a donor whose blood closely resembles the patient's blood will help the patient's bone marrow make new stem cells that become red blood cells, white blood cells, and platelets.

PURPOSE: This phase I/II trial is studying the side effects of total-body irradiation, fludarabine, and thiotepa and to see how well they work in treating young patients who are undergoing a donor stem cell transplant for hematologic cancer.

详细描述

OBJECTIVES:

Primary

  • Determine the safety of a conditioning regimen without anti-thymocyte globulin comprising total body irradiation, thiotepa, and fludarabine followed by CD34-positive-selected haploidentical allogeneic peripheral blood stem cell transplantation in young patients with life-threatening hematologic malignancies.

Secondary

  • Determine the risk for severe graft-vs-host disease in patients treated with this regimen.
  • Determine the kinetics of immune reconstitution in patients treated with this regimen.
  • Determine the risk for life-threatening infections in patients treated with this regimen.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 20 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Safety

次要结局

  • Risk of severe graft-versus-host disease
  • Kinetics of immune reconstitution
  • Risk of life-threatening infections

研究者

申办方类型
Other

研究点 (4)

Loading locations...

相似试验